EQL Pharma AB is a pharmaceutical company based in Lund, Sweden, that specializes in the development, marketing, and sale of generic medicines across Sweden, Denmark, Norway, Finland, and other European countries. Founded in 2006, the company focuses on niche generics—generic drugs that have limited competition due to small global sales but higher turnover in specific regions. EQL Pharma aims to deliver cost-effective, high-quality medicines to pharmacies and hospitals, thereby reducing drug costs for patients and society. As of July 2026, EQL Pharma has launched 47 niche generics in the Nordic markets, with further products planned for future releases. The company had approximately 23 employees and reported a revenue of 432.66 million SEK for the fiscal year 2026, marking a 15.83% increase from the previous year's revenue of 373.52 million SEK. However, EQL Pharma experienced a net loss of 14.04 million SEK during the same period. The company was listed on Nasdaq Stockholm on July 4, 2024. EQL Pharma collaborates with partners in Asia, Europe, and India to develop its products and does not focus on specific therapeutic areas, instead identifying opportunities within the Nordic market for prescription medicines. The company's leadership includes CEO Axel Schörling and founder and chairman Christer Fahraeus.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
EQL Pharma AB's offering is currently approved on OTHER. EQL Pharma AB is headquartered in Sweden. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with EQL Pharma AB.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/eql-pharma-ab" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="EQL Pharma AB — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/eql-pharma-ab?theme=light as the src instead.
https://www.discoveripo.com/ipo/eql-pharma-ab/opengraph-image
EQL Pharma AB IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/eql-pharma-ab?utm_source=embed&utm_medium=text&utm_campaign=eql-pharma-ab
Get emailed when EQL Pharma AB's terms, price, or expected date change — no weekly noise, just this company.
EQL Pharma AB is listing on OTHER.
EQL Pharma AB is a pharmaceutical company based in Lund, Sweden, that specializes in the development, marketing, and sale of generic medicines across Sweden, Denmark, Norway, Finland, and other European countries. Founded in 2006, the company focuses on niche generics—generic drugs that have limited competition due to small global sales but higher turnover in specific regions. EQL Pharma aims to deliver cost-effective, high-quality medicines to pharmacies and hospitals, thereby reducing drug costs for patients and society. As of July 2026, EQL Pharma has launched 47 niche generics in the Nordic markets, with further products planned for future releases. The company had approximately 23 employees and reported a revenue of 432.66 million SEK for the fiscal year 2026, marking a 15.83% increase from the previous year's revenue of 373.52 million SEK. However, EQL Pharma experienced a net loss of 14.04 million SEK during the same period. The company was listed on Nasdaq Stockholm on July 4, 2024. EQL Pharma collaborates with partners in Asia, Europe, and India to develop its products and does not focus on specific therapeutic areas, instead identifying opportunities within the Nordic market for prescription medicines. The company's leadership includes CEO Axel Schörling and founder and chairman Christer Fahraeus.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy